Current Report Filing (8-k)
May 18 2020 - 5:08PM
Edgar (US Regulatory)
0000885725
false
0000885725
2020-05-14
2020-05-14
0000885725
BSX:CommonStock0.01ParValuePerShareMember
2020-05-14
2020-05-14
0000885725
BSX:Sec0.625SeniorNotesDue2027Member
2020-05-14
2020-05-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_____________________________________________________________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
_____________________________________________________________________
Date of Report (Date of earliest event
reported): May 14, 2020
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified
in its charter)
Delaware
|
|
1-11083
|
|
04-2695240
|
(State or other jurisdiction of incorporation or organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
300 Boston Scientific
Way, Marlborough, Massachusetts
01752-1234
(Address of Principal
Executive Offices)
(Zip Code)
508 683-4000
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol
|
|
Name of each exchange on which registered
|
Common Stock, $0.01 par value per share
|
|
BSX
|
|
New York Stock Exchange
|
0.625% Senior Notes due 2027
|
|
BSX27
|
|
New York Stock Exchange
|
Indicate by
check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 1.01 ENTRY INTO A MATERIAL
DEFINITIVE AGREEMENT
On May 14, 2020, Boston Scientific Corporation
(the “Company”) entered into an Underwriting Agreement, (as supplemented by the Terms Agreement, also dated May 14,
2020, the “Underwriting Agreement”), among the Company and Barclays Capital Inc., Citigroup Global Markets Inc., J.P.
Morgan Securities LLC and Wells Fargo Securities, LLC, as representatives of the underwriters named in the Underwriting Agreement
(the “Underwriters”), in connection with the Company’s previously announced pricing of $1.7 billion aggregate
principal amount of senior notes. Pursuant to the Underwriting Agreement, the Underwriters agreed to purchase $500.0 million in
aggregate principal amount of the Company’s 1.900% Senior Notes due 2025 (the “2025 Notes”) and $1.2 billion
in aggregate principal amount of the Company’s 2.650% Senior Notes due 2030 (the “2030 Notes” and, together with
the 2025 Notes, the “Notes”) under the Company’s shelf registration statement on Form S-3 (File No. 333-223095).
The Underwriting Agreement contains customary representations, warranties and agreements of the Company and customary conditions
to closing, indemnification rights and obligations of the parties and termination provisions. The Underwriters and their affiliates
have performed commercial banking, investment banking and advisory services for the Company from time to time for which they have
received customary fees and expenses. The Underwriters and their affiliates may, from time to time, engage in transactions with
and perform services for the Company in the ordinary course of their business.
The Notes were issued pursuant to an indenture
dated as of May 29, 2013 between the Company and U.S. Bank National Association, as trustee (the “Indenture”). The
Indenture contains covenants that restrict the Company’s ability, with certain exceptions, to (i) merge or consolidate with
another entity or transfer all or substantially all of its property and assets, and (ii) incur liens. These covenants are subject
to important exceptions and qualifications, as described in the Indenture. The Indenture also provides for customary events of
default. Additional terms of each series of Notes are set forth in the form of notes corresponding to such series.
The foregoing descriptions of the Underwriting
Agreement, the Indenture and the Notes are summaries and are qualified in their entirety by reference to such documents, which
are attached as Exhibits 1.1, 4.1, 4.2 and 4.3 to this Current Report on Form 8-K, respectively, and all of which are incorporated
herein by reference.
ITEM 8.01 OTHER EVENTS
Closing of Notes Offering
On May 18, 2020, the Company completed
the offering of the Notes. The net proceeds from the offering of the Notes, after deducting underwriting discounts and estimated
offering expenses, were approximately $1,682.2 million. As previously announced, the Company intends to use the net proceeds from
the offering of the Notes towards (i) refinancing $450.0 million of borrowings under its revolving credit facility and a portion
of its pre-payable bank debt, including $750.0 million under its $1.0 billion term loan credit facility maturing in February 2021
and $500.0 million under its $1.25 billion term loan credit facility maturing in April 2021 and (ii) paying related fees, expenses
and premiums.
A copy of the press release pertaining
to the completion of the offering of the Notes is filed with this report as Exhibit 99.1 and incorporated herein by reference.
Additionally, in connection with the offering
of the Notes, the Company is filing a legal opinion regarding the validity of the Notes, attached as Exhibit 5.1 to this Current
Report on Form 8-K.
ITEM 9.01. FINANCIAL STATEMENTS
AND EXHIBITS.
(d) Exhibits
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
1.1*
|
|
Underwriting Agreement, dated as of May 14, 2020, as supplemented by the Terms Agreement, dated May 14, 2020, among Boston Scientific Corporation and Barclays Capital Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC, as representatives of the underwriters.
|
4.1
|
|
Indenture dated as of May 29, 2013, between Boston Scientific Corporation and U.S. Bank National Association, as trustee (filed as Exhibit 4.1 to the Company’s Registration Statement on Form S-3 filed on May 29, 2013 and incorporated herein by reference).
|
4.2*
|
|
Form of 1.900% Senior Note due 2025.
|
4.3*
|
|
Form of 2.650% Senior Note due 2030.
|
5.1*
|
|
Opinion dated May 18, 2020 of Shearman & Sterling LLP.
|
23.1*
|
|
Consent of Shearman & Sterling LLP (included in Exhibit 5.1).
|
99.1*
|
|
Press Release issued by Boston Scientific Corporation dated May 18, 2020.
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
|
|
|
* Documents filed or furnished with this report.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Date:
|
May 18, 2020
|
BOSTON SCIENTIFIC CORPORATION
|
|
|
|
|
|
|
By:
|
/s/ Vance R. Brown
|
|
|
|
Vance R. Brown
|
|
|
|
Vice President and Chief Corporate Counsel
|
Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Apr 2023 to Apr 2024